Savara Inc (SVRA): debt financing — Savara secures up to $200M non-dilutive debt from Hercules Capital, $30M drawn at close

Savara Inc

$30M initial draw used to repay existing $26.5M SVB debt; up to $170M additional available contingent on FDA approval of MOLBREEVI and other milestones.
Interest-only period of 36 months (extendable to 60 months upon FDA approval); floating rate of prime+1.45% (floor 6%+1.45%).
No warrants issued; loan matures April 1, 2030; collateral includes tangible assets (negative pledge on IP).
Milestone triggers: $80M available upon FDA approval (by end of 2025 if priority review), $20M upon revenue milestone post-2027, $70M at Hercules discretion.

item 1.01 item 1.02 item 2.03 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Debt Financings SEC 8-K Item 2.03/2.04 confidence 0.9

Savara Inc incurred term loan of up to $200 million with Hercules Capital, Inc. at greater of (a) the prime rate reported in The Wall Street Journal or (b) 6.0%, p maturing April 1, 2030.

Instrument: term loan
Principal: up to $200 million
Counterparty: Hercules Capital, Inc.
Rate: greater of (a) the prime rate reported in The Wall Street Journal or (b) 6.0%, p
Maturity: April 1, 2030
Event: incurrence

Exact text from the filing

party thereto (the “Lenders”) and Hercules Capital, Inc., as administrative agent and collateral agent (the “Agent”). The Loan Agreement provides for the Company to borrow up to $200 million of term loans (the “Term Loan”) that may be advanced in multiple tranches. The initial advance of $30 million under the Loan Agreement was drawn on the Closing Date and used to

View on SEC.gov

Browse all debt financings →

Savara Inc filing history →

Source: SEC EDGAR

accession 0001193125-25-064145

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.